Skip to content
Sign in
European CDMOs compared · 2026 census

CDMOs in Sweden: 9 compared (2026)

9 of the 255 contract development and manufacturing organisations in A4BEE’s European census are headquartered in Sweden. None has revenue over €1bn. 5 sit between €250m and €1bn and 4 are smaller or niche.

By ownership: 2 family-owned, 2 private equity, 1 listed, 3 part of a pharma or industrial group and 1 state-owned. The most common capabilities are sterile fill-finish (5), oral solid dose (4), small-molecule API (3), biologics and biosimilars (3) and monoclonal antibody (2). 7 of the 9 rows rest on audited reports or official company disclosures; the rest come from secondary sources or estimates.

Open these 9 in the interactive mapAll 255 European CDMOs

9 companies

CDMOs in Sweden

CompanyHQOwnershipSizeRevenue (as reported)ModalitiesData
APL (Apotek Produktion & Laboratorier)State-owned; dual mandate of extemporaneous compounding for Sweden plus a commercial CDMO arm.StockholmState-ownedSwedish StateTier 2not disclosedOral solid dose, Sterile fill-finish, Small-molecule APIhigh
Cobra Biologics (Charles River)Sweden-registered mammalian mAb/recombinant-protein site, now part of US Charles River. Standalone CDMO branding uncertain.SödertäljePart of a pharma or industrial groupCharles RiverTier 2not disclosedMonoclonal antibody, Biologics and biosimilarsmedium
NorthX BiologicsBiologics CDMO built on the former Cobra Biologics Matfors site; Swedish national innovation hub for ATMPs.MatforsPrivate equityFlerie InvestTier 2not disclosedMicrobial and protein, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccine, Cell and gene therapy, Monoclonal antibody, Sterile fill-finishlow
RecipharmStockholmPrivate equityEQTTier 2€827 m (2024)Sterile fill-finish, Oral solid dose, Biologics and biosimilars, mRNA and LNP, Viral vector and vaccinehigh
Sever Pharma SolutionsSpecialist CDMO for high-potent (OEB6)/cytotoxic/hormonal drug products and polymer-based delivery. Formerly QPharma.MalmöFamily-ownedNordic Group (Paulsen family)Tier 2not disclosedOral solid dosehigh
BioglanCDMO specialised in topical semi-solids and liquids (creams, gels, ointments) — dosage forms outside the modality code set. Owned by Spain's Reig Jofré.MalmöPart of a pharma or industrial groupReig JofréTier 3not disclosedOther dose formshigh
GalenicaPrivately owned Swedish CDMO (est. 1999); dev + GMP manufacture of solids, liquids, semi-solids, small molecules and peptides incl. high-potency.MalmöFamily-ownedTier 3not disclosedOral solid dose, Peptide, Small-molecule APIhigh
Magle ChemoswedVertically-integrated CDMO/CMO for pharma and med-tech: intermediates → APIs, niche formulation, fill-finish, QP release. FDA-inspected.MalmöListedTier 3not disclosedSmall-molecule API, Sterile fill-finishhigh
Rechon Life ScienceSterile-injectables CDMO (ampoules, vials, cartridges, PFS) plus nasal/oral sprays. From Ferring's former Malmö plant; Chinese-owned.MalmöPart of a pharma or industrial groupShanghai DongbaoTier 3not disclosedSterile fill-finishhigh

Size: Tier 1 (revenue over €1bn) · Tier 2 (€250m–€1bn) · Tier 3 (under €250m or niche).

Revenue, staff and site figures are as reported and mix audited accounts with commercial estimates, which are often wrong for private companies. Each row carries a confidence mark; verify a figure before quoting it.

Browse the census

Other European CDMO lists